Welcome to our dedicated page for Lipella Pharmaceuticals news (Ticker: LIPO), a resource for investors and traders seeking the latest updates and insights on Lipella Pharmaceuticals stock.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company developing drug reformulations and mucosal delivery approaches for diseases with significant unmet need. News about LIPO centers on its liposomal tacrolimus oral-rinse programs, including clinical data in oral lichen planus, and on CMC manufacturing work for LP-10 and LP-310.
Company updates also cover patent protection for MRI-based diagnostic technology, presentations of study results at medical and investor forums, and corporate-status developments after the delisting of its common stock from the Nasdaq Capital Market. Lipella later reported voluntary Chapter 11 petitions by the company and certain subsidiaries.
Lipella Pharmaceuticals (Nasdaq: LIPO), a clinical-stage biotech firm, announced a presentation by CEO Jonathan Kaufman at the Biotech Showcase 2023 in San Francisco on January 11, 2023, at 2:00 PM PST. The company focuses on reformulating existing drugs for new applications, targeting diseases with no FDA-approved therapies. Lipella aims to meet potential partners and investors at the event and is poised to release Phase 2a trial results for LP-10, addressing radiation-induced hemorrhagic cystitis, a severe condition.